Evidence map›Paper›PMID 27847589›Full record

ArticleSAGE open medical case reports2016

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction.

Heather S Snyder, Benjamin T Duhart, Amy G Krauss, Vinaya Rao

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Heather S SnyderDepartment of Pharmacy, Methodist University Hospital, Memphis, TN, USA; College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.
Benjamin T DuhartDepartment of Pharmacy, Methodist University Hospital, Memphis, TN, USA; College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.
Amy G KraussDepartment of Pharmacy, Methodist University Hospital, Memphis, TN, USA; College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.
Vinaya RaoMethodist University Hospital Transplant Institute and University of Tennessee Health Science Center, Memphis, TN, USA.
Methodist University Hospital · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesConversion from calcineurin inhibitor-based maintenance immunosuppression to belatacept in kidney transplant recipients has been demonstrated to improve renal function while maintaining efficacy against rejection. However, conversion studies to date have excluded patients with an estimated glomerular filtration rate < 35 mL/min/1.73 m

methodsWe describe two patients with an estimated glomerular filtration rate < 30 mL/min/1.73 m

resultsBoth patients experienced improvement in renal function following conversion.

conclusionsThese results suggest that patients with more severe degrees of allograft impairment may benefit from conversion of maintenance calcineurin inhibitor to belatacept-based immunosuppression. Larger, randomized studies are warranted to evaluate the impact of such an approach.

Indexed as

Belataceptcalcineurin inhibitor nephrotoxicitykidney transplantation

Identifiers

PMID27847589
PMCPMC5098796
OpenAlexW2548660892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.